Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Roche swallows US breast cancer drug firm

Share this article

Roche swallows US breast cancer drug firm
Photo: Roche
12:27 CEST+02:00
Swiss pharmaceutical group Roche said on Wednesday that it was buying Seragon Pharmaceuticals, a US biotechnology firm specializing in a new way to fight breast cancer, in a deal worth up to $1.7 billion.

Seragon, a privately held outfit located in California, is developing a new generation of treatments for the most common form of breast cancer, the Basel-based company said in a statement.
   
Roche said its Genentech subsidiary would be acquiring Seragon, putting $725 million in cash upfront and adding up to another $1 billion if "certain predetermined milestones" are met.

The deal is expected to be sealed by the end of September if anti-trust regulators raise no objection.

Get notified about breaking news on The Local

Share this article

Advertisement
Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement